Citations

Clear

246 citation(s) found for "Study, Alfa".

HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advance
Shroff, Rachna T. , Hecht, J. Randolph , Bullock, Andrea J. , Ritch, Paul S., Chondros, Dimitrios, Muhsin, Mann, Oh, Do‐Youn , Borad, Mitesh J. , Abou‐Alfa, Ghassan K.

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: TPS543-TPS543

10.1200/jco.2018.36.4_suppl.tps543 Get It

TPS543 Background: Cholangiocarcinoma (CCA) is treated with CIS and GEM (CISGEM), but prognosis is poor. Hyaluronan (HA) accumulation in solid tumors may impede drug and immune cell access. PEGPH20 targets tumors that accumulate HA (HA-high). This study (NCT03267940) plans to enroll 70 subjects to evaluate the safety and activity of PEGPH20 + programmed cell death-ligand 1 (PD-L1) agent atezolizumab, (PEGCISGEMATEZO), & PEGPH20 + CISGEM (PEGCISGEM) in HA-high subjects with CCA and gallbladder cancer. Study will comprise initial run-in and expansion portions. Primary endpoints include incidence of AEs and other laboratory/safety parameters and ORR (RECIST v1.1). Secondary endpoints include PK parameters; DOR, DCR, PFS, and ORR (RECIST v1.1 and immune-modified RECIST); and OS and OS by PD-L1 expression. Methods: ~6 HA-high subjects will be enrolled in PEGCISGEM arm run-in portion and undergo at ≥1 cycle; subsequently, 6 HA-high subjects will enter the PEGCISGEMATEZO arm. Treatment period will be 21-day cycles. In the expansion portion, ~50 HA-high subjects will be enrolled and randomized in a 2:2:1 ratio into PEGCISGEMATEZO, PEGCISGEM, and CISGEM arms. PEGPH20 is planned to be administered at 3.0 μg/kg on Days 1, 8 and 15 of all cycles in both portions. ATEZO will be administered at 1200 mg 1–3 hours after PEGPH20 on Day 1 of each 21-day cycle in the PEGCISGEMATEZO arm in both portions. In the PEGCISGEM & PEGCISGEMATEZO arms, dosing schedule for CISGEM is the same during both portions, with administration of 25 mg/m2 CIS and 1000 mg/m2 GEM on Days 2 and 9 of each cycle. In CISGEM control arm (expansion only), dosing schedule will be on Days 1 and 8 of each cycle. Treatment will continue until death, withdrawal of consent, disease progression, or unacceptable toxicity. Tumor response will be evaluated using RECIST v1.1. AEs will be graded per NCI CTCAE v4.03. Tumor samples will be tested retrospectively for PD-L1 expression. Safety data will be periodically monitored by an independent data monitoring committee. Clinical trial information: NCT03267940.
A concise and persistent feature to study brain resting‐state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative
Kuang, Liqun , Han, Xie , Chen, Kewei , Caselli, Richard J. , Reiman, Eric M. , Wang, Yalin , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R. , Levey, Allan I. , Kantarci, Kejal , Mathis, Chester A. , Donohue, Michael , DeCarli, Charles , Preda, Adrian , Carrillo, María C. , Turner, Raymond Scott , Bartha, Robert , Pomara, Nunzio , Sadowski, Martin , Arfanakis, Konstantinos , Lamar, Melissa , DeCarli, Charles , Jack, Clifford R , Preda, Adrian , Kantarci, Kejal , Donohue, Michael C , Initiative, for the Alzheimer's Disease Neuroimaging, Wang, Yalin , Levey, Allan I , Jimenez‐Maggiora, Gustavo Adolfo

Mayo Clinic

Human Brain Mapping | December 20, 2018 | Volume: 40 | Issue: 4 | Pages: 1062-1081

10.1002/hbm.24383 | PMID 30569583 Get It

AbstractAlzheimer's disease (AD) is the most common type of dementia in the elderly with no effective treatment currently. Recent studies of noninvasive neuroimaging, resting‐state functional magnetic resonance imaging (rs‐fMRI) with graph theoretical analysis have shown that patients with AD and mild cognitive impairment (MCI) exhibit disrupted topological organization in large‐scale brain networks. In previous work, it is a common practice to threshold such networks. However, it is not only difficult to make a principled choice of threshold values, but also worse is the discard of potential important information. To address this issue, we propose a threshold‐free feature by integrating a prior persistent homology‐based topological feature (the zeroth Betti number) and a newly defined connected component aggregation cost feature to model brain networks over all possible scales. We show that the induced topological feature (Integrated Persistent Feature) follows a monotonically decreasing convergence function and further propose to use its slope as a concise and persistent brain network topological measure. We apply this measure to study rs‐fMRI data from the Alzheimer's Disease Neuroimaging Initiative and compare our approach with five other widely used graph measures across five parcellation schemes ranging from 90 to 1,024 region‐of‐interests. The experimental results demonstrate that the proposed network measure shows more statistical power and stronger robustness in group difference studies in that the absolute values of the proposed measure of AD are lower than MCI and much lower than normal controls, providing empirical evidence for decreased functional integration in AD dementia and MCI.
Multisite study of the relationships between antemortem [ 11 C]PIB‐PET Centiloid values and postmortem measures
Joie, Renaud La , Ayakta, Nagehan , Borys, Ewa, Boxer, Adam L. , DeCarli, Charles , Doré, Vincent , Grinberg, Lea T. , Huang, Eric J. , Hwang, Ji‐Hye , Ikonomović, Miloš D. , Jack, Clifford R. , Jagust, William J. , Jin, Lee‐Way, Klunk, William E. , Kofler, Julia , Lesman‐Segev, Orit H. , Lockhart, Samuel N. , Lowe, Val J. , Masters, Colin L. , Mathis, Chester A. , McLean, Catriona , Miller, Bruce L. , Mungas, Daniel, O’Neil, James P. , Olichney, John , Parisi, Joseph E., Petersen, Ronald C. , Rosen, Howard J. , Vemuri, Prashanthi , Villemagne, Victor L. , Murray, Melissa E. , Rabinovici, Gil D. , DeCarli, Charles , Jack, Clifford R , Vemuri, Prashanthi , Miller, Bruce L , Murray, Melissa E , Masters, Colin L , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Seeley, William W. , Rowe, Christopher Cleon , Spina, Salvatore , Mclean, Catriona , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | October 20, 2018 | Volume: 15 | Issue: 2 | Pages: 205-216

10.1016/j.jalz.2018.09.001 | PMID 30347188 Get It

Abstract Introduction We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [ 11 C]PIB–positron emission tomography ([ 11 C]PIB‐PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ‐PET quantification. Methods Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. Results CL values increased with each CERAD neuritic plaque score increment (median −3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET‐pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate‐to‐frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate‐to‐high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Discussion Our study demonstrated the robustness of a multisite Centiloid [ 11 C]PIB‐PET study and established a range of pathology‐based CL thresholds.
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Veitch, Dallas P. , Weiner, Michael W. , Aisen, Paul, Cairns, Nigel J., Harvey, Danielle , Jack, Clifford R. , Jagust, William J. , Morris, John C. , Petersen, Ronald C. , Shaw, Leslie M. , Toga, Arthur W. , Trojanowski, John Q. , Initiative, Alzheimer's Disease Neuroimaging, Levey, Allan I. , Kantarci, Kejal , Fox, Nick C. , Mathis, Chester A. , Thompson, Paul M. , Donohue, Michael , DeCarli, Charles , Preda, Adrian , Carrillo, María C. , Turner, Raymond Scott , Bartha, Robert , Arfanakis, Konstantinos , Lamar, Melissa , DeCarli, Charles , Jack, Clifford R , Preda, Adrian , Toga, Arthur W , Thompson, Paul M , Kantarci, Kejal , Fox, Nick C , Morris, John C , Donohue, Michael C , Harvey, Danielle J , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Initiative, Alzheimer's Disease Neuroimaging, Levey, Allan I , Jimenez‐Maggiora, Gustavo Adolfo

Mayo Clinic

Alzheimer's & Dementia | October 13, 2018 | Volume: 15 | Issue: 1 | Pages: 106-152

10.1016/j.jalz.2018.08.005 | PMID 30321505 Get It

Abstract Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite, longitudinal, observational study that has collected many biomarkers since 2004. Recent publications highlight the multifactorial nature of late‐onset AD. We discuss selected topics that provide insights into AD progression and outline how this knowledge may improve clinical trials. Methods We used standard methods to identify nearly 600 publications using ADNI data from 2016 and 2017 (listed in Supplementary Material and searchable at http://adni.loni.usc.edu/news‐publications/publications/ ). Results (1) Data‐driven AD progression models supported multifactorial interactions rather than a linear cascade of events. (2) β‐Amyloid (Aβ) deposition occurred concurrently with functional connectivity changes within the default mode network in preclinical subjects and was followed by specific and progressive disconnection of functional and anatomical networks. (3) Changes in functional connectivity, volumetric measures, regional hypometabolism, and cognition were detectable at subthreshold levels of Aβ deposition. 4. Tau positron emission tomography imaging studies detailed a specific temporal and spatial pattern of tau pathology dependent on prior Aβ deposition, and related to subsequent cognitive decline. 5. Clustering studies using a wide range of modalities consistently identified a “typical AD” subgroup and a second subgroup characterized by executive impairment and widespread cortical atrophy in preclinical and prodromal subjects. 6. Vascular pathology burden may act through both Aβ dependent and independent mechanisms to exacerbate AD progression. 7. The APOE ε4 allele interacted with cerebrovascular disease to impede Aβ clearance mechanisms. 8. Genetic approaches identified novel genetic risk factors involving a wide range of processes, and demonstrated shared genetic risk for AD and vascular disorders, as well as the temporal and regional pathological associations of established AD risk alleles. 9. Knowledge of early pathological changes guided the development of novel prognostic biomarkers for preclinical subjects. 10. Placebo populations of randomized controlled clinical trials had highly variable trajectories of cognitive change, underscoring the importance of subject selection and monitoring. 11. Selection criteria based on Aβ positivity, hippocampal volume, baseline cognitive/functional measures, and APOE ε4 status in combination with improved cognitive outcome measures were projected to decrease clinical trial duration and cost. 12. Multiple concurrent therapies targeting vascular health and other AD pathology in addition to Aβ may be more effective than single therapies. Discussion ADNI publications from 2016 and 2017 supported the idea of AD as a multifactorial disease and provided insights into the complexities of AD disease progression. These findings guided the development of novel biomarkers and suggested that subject selection on the basis of multiple factors may lower AD clinical trial costs and duration. The use of multiple concurrent therapies in these trials may prove more effective in reversing AD disease progression.
Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease
Joseph‐Mathurin, Nelly , Jasielec, Mateusz S., Vlassenko, Andrei G. , Gordon, Brian A. , Hornbeck, Russ C. , Cash, Lisa, Veale, Thomas , Cash, David M. , Buckles, Virginia, Cairns, Nigel J. , Goate, Alison , Karch, Celeste M. , Klunk, William E. , Marcus, Daniel S. , Mayeux, Richard , Noble, James M. , Ringman, John M. , Xiong, Chengjie , Morris, John C. , Bateman, Randall J. , Network, Dominantly Inherited Alzheimer, Gordon, Brian A , Bateman, Randall J , Joseph-Mathurin, Nelly , Karch, Celeste M , Morris, John C , Cash, David M , Su, Yi , Blazey, Tyler , Friedrichsen, Karl A. , Ances, Beau M. , Brickman, Adam M. , Cruchaga, Carlos , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Saykin, Andrew J. , Thompson, Paul M. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer, Goate, Alison M , Noble, James M

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | September 27, 2018 | Volume: 10 | Issue: 1 | Pages: 669-677

10.1016/j.dadm.2018.08.012 | PMID 30417072 Get It

AbstractIntroduction18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) is commonly used to estimate neuronal injury in Alzheimer's disease (AD). Here, we evaluate the utility of dynamic PET measures of perfusion using 11C‐Pittsburgh compound B (PiB) to estimate neuronal injury in comparison to FDG PET.MethodsFDG, early frames of PiB images, and relative PiB delivery rate constants (PiB‐R1) were obtained from 110 participants from the Dominantly Inherited Alzheimer Network. Voxelwise, regional cross‐sectional, and longitudinal analyses were done to evaluate the correlation between images and estimate the relationship of the imaging biomarkers with estimated time to disease progression based on family history.ResultsMetabolism and perfusion images were spatially correlated. Regional PiB‐R1 values and FDG, but not early frames of PiB images, significantly decreased in the mutation carriers with estimated year to onset and with increasing dementia severity.DiscussionHypometabolism estimated by PiB‐R1 may provide a measure of brain perfusion without increasing radiation exposure.